Apotex First In US To Recall OTC Ranitidine Tablets Due To NDMA Impurity
Apotex recalls 13 OTC ranitidine tablet products it provided to Walmart, Walgreens and Rite Aid. FDA has no information on plans by nine other firms that, like Apotex, have approved ANDAs for copies of Zantac 75- and 150-mg tablets, which also remain available.
You may also be interested in...
Examples of unfinished business from 2019 include no legislation passed to reform OTC monograph program; FDA putting off until May the planned publication of an NPRM to allow firms to submit OTC NDAs with extra-label information to help guide consumers' self-selection; and no OTC naloxone for opioid overdose approved even after FDA's unprecedented step of developing model DFLs sponsors could use for their own label comprehension studies.
CVS, Walgreen suspend sales of brand and store brand ranitidine OTCs while Sanofi confirms it is not recalling Zantac in the US and has no plans to cease manufacturing or distributing.
Sandoz is voluntarily recalling all ranitidine hydrochloride capsules in the US because of “confirmed’ NDMA contamination, while Dr Reddy’s is suspending global shipments of the generic version of Zantac due to worries about the presence of the suspected cancer-causing agent in its products, as suppliers around the world grapple with the issue.